Longitudinal soluble marker profiles reveal strong association between cytokine storms resulting from macrophage activation and disease severity in COVID-19 disease.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 06 2024
05 06 2024
Historique:
received:
20
02
2024
accepted:
30
05
2024
medline:
6
6
2024
pubmed:
6
6
2024
entrez:
5
6
2024
Statut:
epublish
Résumé
SARS-CoV2 infection results in a range of disease severities, but the underlying differential pathogenesis is still not completely understood. At presentation it remains difficult to estimate and predict severity, in particular, identify individuals at greatest risk of progression towards the most severe disease-states. Here we used advanced models with circulating serum analytes as variables in combination with daily assessment of disease severity using the SCODA-score, not only at single time points but also during the course of disease, to correlate analyte levels and disease severity. We identified a remarkably strong pro-inflammatory cytokine/chemokine profile with high levels for sCD163, CCL20, HGF, CHintinase3like1 and Pentraxin3 in serum which correlated with COVID-19 disease severity and overall outcome. Although precise analyte levels differed, resulting biomarker profiles were highly similar at early and late disease stages, and even during convalescence similar biomarkers were elevated and further included CXCL3, CXCL6 and Osteopontin. Taken together, strong pro-inflammatory marker profiles were identified in patients with COVID-19 disease which correlated with overall outcome and disease severity.
Identifiants
pubmed: 38839796
doi: 10.1038/s41598-024-63586-8
pii: 10.1038/s41598-024-63586-8
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
PTX3 protein
148591-49-5
Serum Amyloid P-Component
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12882Subventions
Organisme : Leiden University Fund
ID : Crowdfunding Wake Up To Corona
Investigateurs
Sesmu M Arbous
(SM)
Bernard M van den Berg
(BM)
Suzanne Cannegieter
(S)
Christa M Cobbaert
(CM)
Anne M van der Does
(AM)
Jacques J M van Dongen
(JJM)
Jeroen Eikenboom
(J)
Mariet C W Feltkamp
(MCW)
Annemieke Geluk
(A)
Jelle J Goeman
(JJ)
Martin Giera
(M)
Thomas Hankemeier
(T)
Mirjam H M Heemskerk
(MHM)
Pieter S Hiemstra
(PS)
Cornelis H Hokke
(CH)
Jacqueline J Janse
(JJ)
Simon P Jochems
(SP)
Marjolein Kikkert
(M)
Lieke Lamont
(L)
Tamás Pongrácz
(T)
Michael R Del Prado
(MR)
Meta Roestenberg
(M)
Hermelijn H Smits
(HH)
Eric J Snijder
(EJ)
Frank J T Staal
(FJT)
Leendert A Trouw
(LA)
Aswin Verhoeven
(A)
Leo G Visser
(LG)
Jutte J C de Vries
(JJC)
David J van Westerloo
(DJ)
Jeanette Wigbers
(J)
Henk J van der Wijk
(HJ)
Robin C van Wissen
(RC)
Manfred Wuhrer
(M)
Maria Yazdanbakhsh
(M)
Mihaela Zlei
(M)
Josine A Oud
(JA)
Meryem Baysan
(M)
Jeanette Wigbers
(J)
Lieke J van Heurn
(LJ)
Susan B Ter Haar
(SB)
Alexandra G L Toppenberg
(AGL)
Laura Heerdink
(L)
Annekee A van IJlzinga Veenstra
(AA)
Anna M Eikenboom
(AM)
Julia M Wubbolts
(JM)
Jonathan Uzorka
(J)
Willem Lijfering
(W)
Romy Meier
(R)
Ingeborg de Jonge
(I)
Sesmu M Arbous
(SM)
Mark G J de Boer
(MGJ)
Anske G van der Bom
(AG)
Olaf M Dekkers
(OM)
Frits Rosendaal
(F)
Informations de copyright
© 2024. The Author(s).
Références
Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636–1643 (2020).
doi: 10.1038/s41591-020-1051-9
pubmed: 32839624
pmcid: 7869028
Bauer, W., Weber, M., Diehl-Wiesenecker, E. et al. Plasma proteome fingerprints reveal distinctiveness and clinical outcome of SARS-CoV-2 infection. Viruses 13 (2021)
Palma Medina, L. M. et al. Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia. Respir. Res. 24, 62 (2023).
doi: 10.1186/s12931-023-02364-y
pubmed: 36829233
pmcid: 9950694
Filbin, M. R. et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep. Med. 2, 100287 (2021).
doi: 10.1016/j.xcrm.2021.100287
pubmed: 33969320
pmcid: 8091031
Perreau, M. et al. The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. Nat. Commun. 12, 4888 (2021).
doi: 10.1038/s41467-021-25191-5
pubmed: 34373466
pmcid: 8352963
van de Veerdonk, F. L. et al. A guide to immunotherapy for COVID-19. Nat. Med. 28, 39–50 (2022).
doi: 10.1038/s41591-021-01643-9
pubmed: 35064248
Gordon, A. C. et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N. Engl. J. Med. 384, 1491–1502 (2021).
doi: 10.1056/NEJMoa2100433
pubmed: 33631065
Moes, D. et al. Towards fixed dosing of tocilizumab in ICU-admitted COVID-19 patients: Results of an observational population pharmacokinetic and descriptive pharmacodynamic study. Clin. Pharmacokinet. 61, 231–247 (2022).
doi: 10.1007/s40262-021-01074-2
pubmed: 34633645
Boone, N. W., Moes, D., Ramiro, S. et al. Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: Less is more. Br. J. Clin. Pharmacol. (2023).
Swets, M. C. et al. A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: A natural experiment due to drug shortages. Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis. 129, 57–62 (2023).
Higgins, A. M. et al. Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. Jama 329, 39–51 (2023).
doi: 10.1001/jama.2022.23257
pubmed: 36525245
Kyriazopoulou, E. et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: A double-blind, randomized controlled phase 3 trial. Nat. Med. 27, 1752–1760 (2021).
doi: 10.1038/s41591-021-01499-z
pubmed: 34480127
pmcid: 8516650
CORIMUNO-19_Collaborative_Group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): A randomised controlled trial. Lancet Respir. Med. 9, 295–304 (2021).
doi: 10.1016/S2213-2600(20)30556-7
Kyriazopoulou, E., Panagopoulos, P., Metallidis, S. et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. eLife 10 (2021)
Segala, F. V. et al. Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study. PloS One 18, e0273202 (2023).
doi: 10.1371/journal.pone.0273202
pubmed: 37014833
pmcid: 10072376
Monk, P. D. et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 9, 196–206 (2021).
doi: 10.1016/S2213-2600(20)30511-7
pubmed: 33189161
Roukens, A. H. E. et al. Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8(+) T cell responses following COVID-19. Nat. Immunol. 23, 23–32 (2022).
doi: 10.1038/s41590-021-01095-w
pubmed: 34937933
Zlei, M., Sidorov, I. A., Joosten, S. A. et al. Immune Determinants of Viral Clearance in Hospitalised COVID-19 Patients: Reduced Circulating Naïve CD4+ T Cell Counts Correspond with Delayed Viral Clearance. Cells 11 (2022)
Pongracz, T. et al. Immunoglobulin G1 Fc glycosylation as an early hallmark of severe COVID-19. EBioMedicine 78, 103957 (2022).
doi: 10.1016/j.ebiom.2022.103957
pubmed: 35334306
pmcid: 8938159
Pierneef, L. et al. Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19. iScience 26, 105873 (2023).
doi: 10.1016/j.isci.2022.105873
pubmed: 36590898
Escribano, P. et al. Detection of SARS-CoV-2 antibodies is insufficient for the diagnosis of active or cured COVID-19. Sci. Rep. 10, 19893 (2020).
doi: 10.1038/s41598-020-76914-5
pubmed: 33199713
pmcid: 7669901
Maine, G. N. et al. Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect. J. Clin. Virol. 133, 104663 (2020).
doi: 10.1016/j.jcv.2020.104663
pubmed: 33161369
pmcid: 7590643
Joosten, S. A. et al. Daily disease severity in patients with COVID-19 admitted to the hospital: The SCODA (severity of coronavirus disease assessment) score. PloS One 18, e0291212 (2023).
doi: 10.1371/journal.pone.0291212
pubmed: 37683031
pmcid: 10490882
van Meijgaarden, K. E. et al. Cross-laboratory evaluation of multiplex bead assays including independent common reference standards for immunological monitoring of observational and interventional human studies. PloS One 13, e0201205 (2018).
doi: 10.1371/journal.pone.0201205
pubmed: 30180167
pmcid: 6122788
Engel, J. J. et al. Dexamethasone attenuates interferon-related cytokine hyperresponsiveness in COVID-19 patients. Front. Immunol. 14, 1233318 (2023).
doi: 10.3389/fimmu.2023.1233318
pubmed: 37614228
pmcid: 10442808